Loading stock data…
IRWD
$4.17-0.05 (-1.18%)
Market ClosedLast close May 11
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ironwood Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.17. The stock is currently 28% below its 52-week high of $5.78, remaining 42.8% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why IRWD maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.17
Potential Downside
38.3%
Whystock Fair Value$2.57
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Buy
Mean target$6.10+46.3%
Range$3.70 – $10.00
Fundamentals
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase typ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$640.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.20
Beta
Defensive asset. Lower volatility than the S&P 500.
0.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.17%
Volume
Today's trading volume
2.05M
Recent News
Ironwood Pharmaceuticals Q1 Earnings Call Highlights
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF). Ch
Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of +242.86% and +44.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On February 26, Citizens analyst Jason Butler maintained an Outperform rating on Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD). The firm increased its price target from $8 to $10. Citizens noted that the company’s fourth-quarter results were in […]
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?
Ironwood slides 14% in a month on weak Linzess Q4 sales, but strong demand, partnerships, and an upbeat 2026 outlook raise investor optimism.